Myelofibrosis historical perspective: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myelofibrosis}}
{{Myelofibrosis}}
{{CMG}}{{AE}}{{MJK}}, {{SR}}
{{CMG}}{{AE}}{{Sab}}


==Overview==
==Overview==
The first description of primary myelofibrosis (PMF) is credited to a German surgeon, Gustav Heuck, who described the concept in 1879. Additional work and discoveries started to get documented at the beginning of the twentieth century. The substantial contribution came from Max Askanazy, a German pathologist and Herbert Assmann, an Internist from Germany. The condition was given several pseudonyms before the International Working Group for Myelofibrosis Research and Treatment decided in 2006 to use the term primary myelofibrosis (PMF).
The first description of primary [[myelofibrosis]] (PMF) is credited to a German [[surgeon]], Gustav Heuck, who described the concept in 1879. Additional work and discoveries started to get documented at the beginning of the twentieth century. The substantial contribution came from Max Askanazy, a German [[pathologist]] and Herbert Assmann, an [[Internist]] from Germany. The condition was given several pseudonyms before the International Working Group for Myelofibrosis Research and Treatment decided in 2006 to use the term primary [[myelofibrosis]] (PMF).


==Historical Perspective==
==Historical Perspective==
*Gustav Heuck, a German surgeon, was the first to describe the notion of myelofibrosis in 1879. He explained the idea under the title of 'Two cases of leukemia with peculiar blood and bone marrow findings'. Heuck described two patients with massive splenomegaly, increased number of morphologically abnormal leukocytes, and nucleated red blood cells. He observed that the clinical findings in these two patients were different from those described for chronic myelogenous leukemia (CML) because of the presence of marrow fibrosis and extensive extramedullary hematopoiesis (EMH). He also noted osteosclerosis in an autopsy report.<ref>{{cite book | last = Ansell | first = Stephen | title = Rare hematological malignancies | publisher = Springer | location = New York, NY London | year = 2008 | isbn = 9780387737430 }}</ref>
*In 1879, Gustav Heuck, a German [[surgeon]], was the first to describe the notion of [[myelofibrosis]]. He explained the idea under the title of "Two cases of [[leukemia]] with peculiar [[blood]] and [[bone marrow]] findings". Heuck described two patients with massive [[splenomegaly]], increased number of [[Morphology|morphologically]] abnormal [[leukocytes]], and [[nucleated]] [[Red blood cell|red blood cells]]. He observed that the clinical findings in these two patients were different from those described for [[Chronic myelogenous leukemia|chronic myelogenous leukemia (CML)]] because of the presence of [[bone marrow]] [[fibrosis]] and extensive [[Extramedullary hematopoiesis|extramedullary hematopoiesis (EMH)]]. He also noted [[osteosclerosis]] in an [[autopsy]] report.<ref>{{cite book | last = Ansell | first = Stephen | title = Rare hematological malignancies | publisher = Springer | location = New York, NY London | year = 2008 | isbn = 9780387737430 }}</ref>
*In 1904, Max Askanazy, a German pathologist, reported a case with significant extramedullary hematopoiesis of the liver and diffuse bone marrow fibrosis.<ref name="Tefferi2007">{{cite journal|last1=Tefferi|first1=A|title=The history of myeloproliferative disorders: before and after Dameshek|journal=Leukemia|volume=22|issue=1|year=2007|pages=3–13|issn=0887-6924|doi=10.1038/sj.leu.2404946}}</ref>
*In 1904, Max Askanazy, a German [[pathologist]], reported a case with significant [[Extramedullary hematopoiesis|extramedullary hematopoiesis (EMH)]] of the [[liver]] and diffuse [[bone marrow]] [[fibrosis]].<ref name="Tefferi2007">{{cite journal|last1=Tefferi|first1=A|title=The history of myeloproliferative disorders: before and after Dameshek|journal=Leukemia|volume=22|issue=1|year=2007|pages=3–13|issn=0887-6924|doi=10.1038/sj.leu.2404946}}</ref>
*In 1907, Herbert Assmann, an internist from Germany, described another case of extramedullary hematopoiesis and bone marrow fibrosis which went on and named ‘osteosclerotic anemia’. Later on, it was referred to as ‘Heuck–Assmann syndrome’.
*In 1907, Herbert Assmann, an [[internist]] from Germany, described another case of [[Extramedullary hematopoiesis|extramedullary hematopoiesis (EMH)]] and [[bone marrow]] [[fibrosis]] which he went on and named "[[Osteosclerosis|osteosclerotic]] [[anemia]]". Later on, it was referred to as "Heuck–Assmann syndrome".<ref name="Tefferi2007">{{cite journal|last1=Tefferi|first1=A|title=The history of myeloproliferative disorders: before and after Dameshek|journal=Leukemia|volume=22|issue=1|year=2007|pages=3–13|issn=0887-6924|doi=10.1038/sj.leu.2404946}}</ref>
*In 1914, Hans Hirschfeld, a German hematologist further elaborated the splenic pathology in primary myelofibrosis (PMF).
*In 1914, Hans Hirschfeld, a German [[hematologist]] further elaborated the [[splenic]] [[pathology]] in [[Primary myelofibrosis|primary myelofibrosis (PMF)]].
*The concept of [[myeloproliferative disorder]]s (MPDs) was described by William Dameshek, in 1951, by bringing together these five clinicopathologic entities: [[chronic myelogenous leukemia]] (CML), [[polycythemia vera]] (PV), [[essential thrombocythemia]] (ET), primary myelofibrosis (PMF), and [[erythroleukemia]].<ref name="Tefferi2007">{{cite journal|last1=Tefferi|first1=A|title=The history of myeloproliferative disorders: before and after Dameshek|journal=Leukemia|volume=22|issue=1|year=2007|pages=3–13|issn=0887-6924|doi=10.1038/sj.leu.2404946}}</ref>
*In 1951, William Dameshek, an internationally renowned American [[hematologist]], grouped together [[Primary myelofibrosis|primary myelofibrosis (PMF)]], [[Chronic myelogenous leukemia|chronic myelogenous leukemia (CML)]], [[Polycythemia vera|polycythemia vera (PV)]], and [[Essential thrombocythemia|essential thrombocythemia (ET)]] and classified them as "[[Myeloproliferative neoplasm|myeloproliferative disorders]]".<ref name="pmid14820991">{{cite journal |vauthors=DAMESHEK W |title=Some speculations on the myeloproliferative syndromes |journal=Blood |volume=6 |issue=4 |pages=372–5 |date=April 1951 |pmid=14820991 |doi= |url=}}</ref><ref name="pmid17882283">{{cite journal |vauthors=Tefferi A |title=The history of myeloproliferative disorders: before and after Dameshek |journal=Leukemia |volume=22 |issue=1 |pages=3–13 |date=January 2008 |pmid=17882283 |doi=10.1038/sj.leu.2404946 |url=}}</ref>
*The World Health Organization utilizes the name "chronic idiopathic myelofibrosis", while the International Working Group on Myelofibrosis Research and Treatment calls the disease "primary myelofibrosis".<ref name=historyofmyelofibrosiswiki1>History of myelofibrosis. Wikipedia 2016. https://en.wikipedia.org/wiki/Myelofibrosis. Accessed on March 7, 2016</ref>
*In 1975, Murray N Silverstein, an American [[hematologist]], published his classic monograph and described most of the modern natural history and treatment of [[Primary myelofibrosis|primary myelofibrosis (PMF)]].<ref>{{cite book | last = Silverstein | first = Murray | title = Agnogenic myeloid metaplasia | publisher = Pub. Sciences Group | location = Acton, Mass | year = 1975 | isbn = 088416022X }}</ref>


==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Disease]]
[[Category:Medicine]]
[[Category:Types of cancer]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Catgeory:Oncology]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Neurosurgery]]
[[Category:Neurosurgery]]
[[Category:Up-To-Date]]

Latest revision as of 22:50, 29 July 2020

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis historical perspective

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis historical perspective

CDC on Myelofibrosis historical perspective

Myelofibrosis historical perspective in the news

Blogs on Myelofibrosis historical perspective

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

The first description of primary myelofibrosis (PMF) is credited to a German surgeon, Gustav Heuck, who described the concept in 1879. Additional work and discoveries started to get documented at the beginning of the twentieth century. The substantial contribution came from Max Askanazy, a German pathologist and Herbert Assmann, an Internist from Germany. The condition was given several pseudonyms before the International Working Group for Myelofibrosis Research and Treatment decided in 2006 to use the term primary myelofibrosis (PMF).

Historical Perspective

References

  1. Ansell, Stephen (2008). Rare hematological malignancies. New York, NY London: Springer. ISBN 9780387737430.
  2. 2.0 2.1 Tefferi, A (2007). "The history of myeloproliferative disorders: before and after Dameshek". Leukemia. 22 (1): 3–13. doi:10.1038/sj.leu.2404946. ISSN 0887-6924.
  3. DAMESHEK W (April 1951). "Some speculations on the myeloproliferative syndromes". Blood. 6 (4): 372–5. PMID 14820991.
  4. Tefferi A (January 2008). "The history of myeloproliferative disorders: before and after Dameshek". Leukemia. 22 (1): 3–13. doi:10.1038/sj.leu.2404946. PMID 17882283.
  5. Silverstein, Murray (1975). Agnogenic myeloid metaplasia. Acton, Mass: Pub. Sciences Group. ISBN 088416022X.